Reducing the risk of COVID-19 in research that involves interrupting ART
Simon Collins, HIV i-Base
These two papers, published as letters in JAIDS, discuss ways to reduce risks to participants in cure-related studies that involve a treatment interruption.
Some earlier studies were rightly put on hold during the early pandemic but wider availability of vaccines have enabled many of these studies to now reopen.
- Peluso ML et al. SARS-CoV-2 booster vaccination for participants in “HIV cure”-related clinical trials. JAIDS. Letter. doi: 10.1097/QAI.0000000000002875. (26 November 2021).
- Peluso ML et al. SARS-CoV-2 Vaccination in the context of ongoing HIV cure-related research studies. JAIDS JAIDS. Letter, 87(4)e232-e233. doi: 10.1097/QAI.0000000000002690. (1 August 2021).